Allergies, Antibody, Dermatology and Genetics

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Allergies

Antibody

Dermatology

Genetics

TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress

The Pharma Data

JULY 11, 2021

3 These data are being presented at the 2021 European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Krakow, Poland and Madrid, Spain. Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. All antibody titres were low. Markus Magerl, M.D.,

Allergies

Allergies Antibody Recombinant DNA Technology Production

TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met its Objectives in Children Ages 2 to

The Pharma Data

APRIL 13, 2022

“I’m pleased that TAKHZYRO has met these key objectives and I look forward to Takeda sharing further insights with the HAE community in the near future,” said Dr. Marcus Maurer, Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin, Germany and principal investigator of SHP643-301.

Dermatology

Dermatology Allergies Genetics Antibody

Clinical Research Informer

TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress

TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met its Objectives in Children Ages 2 to

Stay Connected